BKX-001
/ BAKX Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 27, 2021
Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway
(Businesswire)
- "Ipsen...and BAKX Therapeutics Inc. have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors...Under the agreement, Ipsen will pay BAKX Therapeutics Inc. $14.5m upon closing, comprising an equity investment and an upfront payment, followed by up to $837.5m in milestone payments. The companies would also share equally costs and profits."
Licensing / partnership • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1